,20 In this study, we evaluated the potential of early tumor shrinkage and depth of response as surrogate endpoints for overall survival and postprogression survival, defined as survival following first-line therapy, in patients treated with chemotherapy plus an anti-EGFR antibody or bevacizumab. This evidence concerns the gene EGFR and neoplasm.